David Preiss
Impact in
-
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Surgery top 0.2%
- Lipoproteins and Cardiovascular Health
Papers in
-
- Diabetes Treatment and Management 29
- Diabetes, Cardiovascular Risks, and Lipoproteins 26
- Surgery 57
- Lipoproteins and Cardiovascular Health 54
- Co-authors
- Naveed A. Sattar (75 shared papers)John J.V. McMurray (22 shared papers)Søren Lund Kristensen (6 shared papers)Pardeep S. Jhund (6 shared papers)Mark Colquhoun Petrie (5 shared papers)Lars Køber (3 shared papers)Rasmus Rørth (1 shared paper)Kieran F. Docherty (1 shared paper)
- Journals
- The Lancet Diabetes & Endocrinology (25 papers)The Lancet (13 papers)Diabetologia (8 papers)Diabetic Medicine (6 papers)Atherosclerosis (5 papers)
- Partner nations
- United KingdomUnited StatesNetherlands
In The Last Decade
David Preiss
150 papers receiving 17.1k citations
David Preiss's Hit Papers
Peers
Comparison fields: 5 of 156
- Endocrinology, Diabetes and Metabolism 4.2k
- Surgery 6.3k
- Nephrology 1.4k
- Cardiology and Cardiovascular Medicine 2.4k
- Epidemiology 1.4k
Countries citing papers authored by David Preiss
This map shows the geographic impact of David Preiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Preiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Preiss more than expected).
Fields of papers citing papers by David Preiss
This network shows the impact of papers produced by David Preiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Preiss. The network helps show where David Preiss may publish in the future.
Co-authors
The 25 scholars most cited alongside David Preiss, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 158 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Hit paper breakdown → | 2010 | 1958 |
| 2 | Interpretation of the evidence for the efficacy and safety of statin therapy Hit paper breakdown → | 2016 | 1457 |
| 3 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Hit paper breakdown → | 2019 | 1316 |
| 4 | Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy Hit paper breakdown → | 2011 | 1163 |
| 5 | Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials Hit paper breakdown → | 2009 | 1091 |
| 6 | Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials Hit paper breakdown → | 2022 | 760 |
| 7 | Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials Hit paper breakdown → | 2019 | 607 |
| 8 | Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Hit paper breakdown → | 2019 | 565 |
| 9 | HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials Hit paper breakdown → | 2014 | 549 |
| 10 | GDF15 mediates the effects of metformin on body weight and energy balance Hit paper breakdown → | 2019 | 454 |
| 11 | Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance Hit paper breakdown → | 2016 | 440 |
| 12 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 13 | Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk Hit paper breakdown → | 2020 | 354 |
| 14 | PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study Hit paper breakdown → | 2016 | 313 |
| 15 | 2014 | 288 | |
| 16 | 2016 | 282 | |
| 17 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 18 | 2010 | 267 | |
| 19 | 2016 | 255 | |
| 20 | Cardiac Troponin T and Troponin I in the General Population Hit paper breakdown → | 2019 | 254 |
About David Preiss
David Preiss is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery, Nephrology, Cardiology and Cardiovascular Medicine and Ophthalmology, having authored 158 papers that have together received 18k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (54 papers), Diabetes Treatment and Management (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (26 papers), Heart Failure Treatment and Management (15 papers), Chronic Kidney Disease and Diabetes (13 papers), Liver Disease Diagnosis and Treatment (10 papers), Retinal Diseases and Treatments (8 papers) and Genetic Associations and Epidemiology (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (4.2k citations), Surgery (6.3k citations), Nephrology (1.4k citations), Cardiology and Cardiovascular Medicine (2.4k citations) and Epidemiology (1.4k citations). David Preiss has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Naveed A. Sattar, John J.V. McMurray, Søren Lund Kristensen, Pardeep S. Jhund, Mark Colquhoun Petrie, Lars Køber, Rasmus Rørth, Kieran F. Docherty, Kausik Kumar Ray and Sreenivasa Rao Kondapally Seshasai. Their work appears in journals such as The Lancet Diabetes & Endocrinology, The Lancet, Diabetologia, Diabetic Medicine and Atherosclerosis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.